靶向递送策略在炎症性肺部疾病中的研究进展  

Research progress on targeted drug delivery strategies in inflammatory lung diseases

作　　者：李晓楠 李阳 许张茜 康淑珍 孔丽 张志平 LI Xiaonan;LI Yang;XU Zhangxi;KANG Shuzhen;KONG Li;ZHANG Zhiping(Tongji School of Pharmacy,Huazhong University of Science and Technology,Wuhan 430030,Hubei,China)

机构地区：[1]华中科技大学同济医学院药学院,湖北武汉430030

出　　处：《中国临床药理学与治疗学》2025年第3期313-324,共12页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金面上项目(82173760,82373816)。

摘　　要：炎症性肺部疾病是目前威胁人类生命健康的重大难题,过度炎症可导致组织损伤,并可引发系统性疾病的发生发展,抗炎治疗对提升患者生存状态与生活质量有着至关重要的意义。近年来,药物靶向递送策略的探索与研究取得了显著进展,有效解决药物递送过程中的起效缓慢、生物利用度低及体内清除速率快等问题。药物靶向递送能够提高局部血药浓度,具有降低给药频率和副作用等优势。本文主要阐述了炎症性肺部疾病的分类及特点,并从局部递送、被动靶向与主动靶向三个层面,综述针对炎症性肺部疾病的靶向递药策略,并展望了药物靶向治疗肺部疾病的前景与面临的挑战,有望为炎症性肺部疾病的治疗提供新的研究应用思路。Inflammatory lung diseases are currently a major challenge threatening human health and life.Imbalanced inflammation and excessive inflammation can lead to tissue damage and trigger the occurrence and development of systemic diseases.Anti-inflammatory treatment is of vital importance for improving patient survival and quality of life.In recent years,significant progress has been made in the exploration and research of drug targeting strategies,effectively addressing issues such as slow onset,low bioavailability,and rapid in vivo clearance rates during drug delivery.Drug targeting can increase local drug concentrations,reduce dosing frequency,and mitigate side effects.This review primarily elaborates on the classification and characteristics of inflammatory lung diseases.It comprehensively reviews targeted drug delivery strategies for inflammatory lung diseases from three perspectives:local targeting,passive targeting,and active targeting.Furthermore,it discusses the prospects and challenges of drug targeted therapy for lung diseases,potentially providing new research and application ideas for the targeted treatment of inflammatory lung diseases.

关 键 词：炎症性疾病 肺部疾病 靶向递送 纳米药物 

分 类 号：R94[医药卫生—药剂学] R563.1[医药卫生—药学]